Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* be 40 - 70 years of age, inclusive~* be seronegative for hepatitis B surface antigen (HBsAg), antibody against hepatitis B surface antigen (anti-HBsAg), antibody against hepatitis B core antigen (anti-HBcAg), and human immunodeficiency virus (HIV)~* be in good health in the opinion of the investigator, based upon medical history, physical examination, and laboratory evaluation~* if female of childbearing potential, agree to consistently use a highly effective method of birth control from screening visit through the treatment phase, for up to 28 days after the last injection~Exclusion Criteria:~* if female of childbearing potential, is pregnant, breastfeeding, or planning a pregnancy~* has a history of or is considered by the investigator to be at high risk for recent exposure to HBV or HIV; for example, current intravenous drug use or has unprotected sex with known HBV/HIV positive partner~* has a known history of autoimmune disease~* has previously received any hepatitis B vaccine (approved or investigational)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- HEPLISAV and/or Placebo (Type: EXPERIMENTAL): 0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
- Engerix-B(1) (Type: ACTIVE_COMPARATOR): 1.0 mL Engerix-B

Based on this trial design, predict the completion outcome and termination type (if applicable).